TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Iterum Therapeutics ( (ITRM) ) just unveiled an announcement.
Iterum Therapeutics has announced that its 2025 Annual General Meeting of Shareholders will be held on September 10, 2025. The company has set July 28, 2025, as the deadline for the submission of shareholder proposals and nominations, due to a change in the meeting date from the previous year. This announcement is significant for shareholders as it outlines the requirements and deadlines for participating in the meeting, which could impact shareholder engagement and decision-making processes.
The most recent analyst rating on (ITRM) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.
Spark’s Take on ITRM Stock
According to Spark, TipRanks’ AI Analyst, ITRM is a Underperform.
Iterum Therapeutics faces significant financial challenges with ongoing net losses and cash flow issues, despite positive developments such as FDA approval of ORLYNVAH. The technical indicators suggest weak market momentum, and valuation metrics reflect poor investment attractiveness. The potential market for ORLYNVAH and improved financial performance are notable positives, but strategic uncertainties and financial obligations weigh heavily on the stock’s outlook.
To see Spark’s full report on ITRM stock, click here.
More about Iterum Therapeutics
Iterum Therapeutics is a pharmaceutical company that focuses on developing anti-infectives aimed at combating multi-drug resistant pathogens. The company is primarily engaged in the healthcare industry, providing innovative solutions to address unmet medical needs in infectious diseases.
Average Trading Volume: 606,667
Technical Sentiment Signal: Sell
Current Market Cap: $38.8M
For a thorough assessment of ITRM stock, go to TipRanks’ Stock Analysis page.